Compare QNC & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | QNC | LXEO |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | Canada | United States |
| Employees | 5 | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 434.7M | 396.5M |
| IPO Year | 2026 | 2023 |
| Metric | QNC | LXEO |
|---|---|---|
| Price | $2.07 | $4.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $18.44 |
| AVG Volume (30 Days) | ★ 1.2M | 962.4K |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.81 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $654,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.90 | $3.60 |
| 52 Week High | $3.59 | $10.99 |
| Indicator | QNC | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 27.63 | 45.39 |
| Support Level | $1.90 | $4.27 |
| Resistance Level | $3.01 | $5.36 |
| Average True Range (ATR) | 0.18 | 0.35 |
| MACD | -0.09 | -0.01 |
| Stochastic Oscillator | 0.88 | 22.86 |
Quantum eMotion Inc is dedicated to developing of a new generation of quantum-safe encryption for the quantum computing age. It is a developer of a new generation of cryptographic solutions under the acquisition of licenses. It allows clients and partners to develop secure quantum-safe encryption that can protect anything from consumer and enterprise devices like mobile phones, computers, the Internet of Things, and networking equipment to demanding cloud-based applications, servers, and military devices.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.